CA2566535A1 - Molecules de reciblage d'ige, alterant les fonctions (erfam), pour traiter des maladies allergiques - Google Patents

Molecules de reciblage d'ige, alterant les fonctions (erfam), pour traiter des maladies allergiques Download PDF

Info

Publication number
CA2566535A1
CA2566535A1 CA002566535A CA2566535A CA2566535A1 CA 2566535 A1 CA2566535 A1 CA 2566535A1 CA 002566535 A CA002566535 A CA 002566535A CA 2566535 A CA2566535 A CA 2566535A CA 2566535 A1 CA2566535 A1 CA 2566535A1
Authority
CA
Canada
Prior art keywords
erfam
ige
antibody
composition
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002566535A
Other languages
English (en)
Inventor
Gideon Lack
Victor Turcanu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ST MARY'S HOSPITAL NHS TRUST
Ip2ipo Innovations Ltd
Original Assignee
St. Mary's Hospital Nhs Trust
Imperial College Innovations Limited
Gideon Lack
Victor Turcanu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St. Mary's Hospital Nhs Trust, Imperial College Innovations Limited, Gideon Lack, Victor Turcanu filed Critical St. Mary's Hospital Nhs Trust
Publication of CA2566535A1 publication Critical patent/CA2566535A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002566535A 2004-05-20 2005-05-19 Molecules de reciblage d'ige, alterant les fonctions (erfam), pour traiter des maladies allergiques Abandoned CA2566535A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57282104P 2004-05-20 2004-05-20
US60/572,821 2004-05-20
PCT/IB2005/003950 WO2006048781A2 (fr) 2004-05-20 2005-05-19 Molecules de reciblage d'ige, alterant les fonctions (erfam), pour traiter des maladies allergiques

Publications (1)

Publication Number Publication Date
CA2566535A1 true CA2566535A1 (fr) 2006-05-11

Family

ID=36319549

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002566535A Abandoned CA2566535A1 (fr) 2004-05-20 2005-05-19 Molecules de reciblage d'ige, alterant les fonctions (erfam), pour traiter des maladies allergiques

Country Status (6)

Country Link
EP (1) EP1781269A2 (fr)
JP (1) JP2008513351A (fr)
CN (1) CN101522714A (fr)
AU (1) AU2005300261A1 (fr)
CA (1) CA2566535A1 (fr)
WO (1) WO2006048781A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2853545T1 (sl) 2008-09-17 2016-10-28 Xencor Inc., Protitelesa, specifična za IgE
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
CN103175954A (zh) * 2013-03-08 2013-06-26 北京海瑞祥天生物科技有限公司 人IgE抗体检测试剂盒、制备方法及检测方法
CN103145832B (zh) * 2013-03-21 2015-01-21 江南大学 一种头孢类药物通用人工抗原的合成方法
EP3538558A4 (fr) * 2016-11-09 2020-07-15 North Carolina State University Traitement de maladies allergiques au moyen d'une protéine chimérique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4538192B2 (ja) * 2001-05-01 2010-09-08 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫疾患を治療するための融合分子及び方法
MXPA03011499A (es) * 2001-06-15 2004-04-05 Tanox Inc Proteinas de fusion de fce para el tratamiento de alergia y asma.
US7488804B2 (en) * 2005-02-02 2009-02-10 The Regents Of The University Of California Modified fusion molecules for treatment of allergic disease

Also Published As

Publication number Publication date
JP2008513351A (ja) 2008-05-01
AU2005300261A1 (en) 2006-05-11
WO2006048781A3 (fr) 2008-02-14
WO2006048781A2 (fr) 2006-05-11
EP1781269A2 (fr) 2007-05-09
CN101522714A (zh) 2009-09-02

Similar Documents

Publication Publication Date Title
TWI660972B (zh) 抗ｍｃａｍ抗體及相關使用方法
EP1730194B1 (fr) Complexes bi-specifiques pour le ciblage de cellules impliquees dans des reactions de type allergique, compositions et utilisations associees
JP7102496B2 (ja) 免疫療法における改変Ｆｃ断片の使用
Cook et al. Identification of contact residues in the IgE binding site of human FcεRIα
US9090709B2 (en) Anti-SEMA4D antibodies and epitopes
JP6397938B2 (ja) Ｂリンパ球のＣＤ２３と架橋するが肥満細胞を感作しないヒト化抗ＩｇＥ抗体
IL202107A (en) An isolated or part of an antibody that binds an antigen, the tlr4 binder and / or the tlr4 / md2 complex and their uses
KR20200104342A (ko) Cd22에 결합하는 중쇄 항체
CA2566535A1 (fr) Molecules de reciblage d'ige, alterant les fonctions (erfam), pour traiter des maladies allergiques
CN110382528A (zh) 治疗或预防认知障碍的人源化抗体、其生产方法及使用其用于治疗或预防认识障碍的剂
Sayers et al. Amino acid residues that influence FcεRI-mediated effector functions of human immunoglobulin E
CA3084602A1 (fr) Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
JP2020048562A (ja) 新規な抗−Ｆｃ−ガンマレセプタＩＩＢ抗体およびその使用
Khodoun et al. Rapid desensitization of humanized mice with anti-human FcεRIα monoclonal antibodies
JP2010524475A (ja) オステオポンチンの機能エピトープ、それと特異的に結合するモノクローナル抗体及び用途
USRE42324E1 (en) Compound for treatment of allergy and asthma
Laffer et al. A molecular model of type I allergy: Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcϵRI interaction and reacts with receptor-bound IgE
JP2022539667A (ja) 抗ＩｇＥ構築物
EP1123317A1 (fr) Variants d'immunoglobuline
EP2258727A1 (fr) Préparation d'immunoglobuline pour le traitement des maladies auto-immunes et troubles du système immunitaire
JP2023542389A (ja) 自己抗体で媒介される状態の予防又は治療のための化合物
AU2002251624A1 (en) Novel compound for treatment of allergy and asthma
WO2024023346A1 (fr) Anticorps igm dégradant l'igg
JP2023503714A (ja) 抗ｅ－セレクチン抗体、組成物および使用の方法
CN116710143A (zh) 用于预防或治疗重症肌无力的化合物

Legal Events

Date Code Title Description
FZDE Dead